Download Files:
Products Details
Product Description
– Fesoterodine-d7 (fumarate) is the deuterium labeled Fesoterodine fumarate[1]. Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB)[2][3].
Web ID
– HY-A0030S
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C30H34D7NO7
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18.|[3]Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats.|[4]Peter Ney, et al. Pharmacological Characterization of a Novel Investigational Antimuscarinic Drug, Fesoterodine, in Vitro and in Vivo. BJU Int. 2008 Apr101(8):1036-42.|[5]Martin C Michel, et al. Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome. Expert Opin Pharmacother. 2008 Jul9(10):1787-96.
CAS Number
– 2747918-94-9
Molecular Weight
– 534.69
SMILES
– [2H]C([2H])([2H])C(C([2H])([2H])[2H])([2H])C(OC1=C([C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2)C=C(CO)C=C1)=O.OC(/C=C/C(O)=O)=O
Clinical Information
– No Development Reported
Solubility
– 10 mM in DMSO
Target
– mAChR
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
